Samsung Bioepis Goes After Lucentis With 40% Cheaper Byooviz Launch In US
Delivers Global First With Ranibizumab Biosimilar Launch Through Partner Biogen
Executive Summary
Samsung Bioepis and Biogen have come in with a hefty discount as they mark a major milestone by launching their Byooviz biosimilar ranibizumab rival to Lucentis in the US.
You may also be interested in...
Regeneron ‘Shocked’ At Biogen Lucentis Biosimilar Sales
With its own interests in the branded eye-disease space, Regeneron has commented on ranibizumab biosimilar sponsor Biogen’s fortunes during a recent conference.
Humira LOE Is ‘Uncharted Territory’ As Fierce Competition Expected
Discussing the latest developments in the US biosimilars market, AmerisourceBergen’s senior director of biosimilar commercialization, Brian Biehn, talks about what we can expect from competition to Humira in 2023, how the first ophthalmology biosimilars are faring, and potential changes on the horizon at the FDA that could smooth the path to market for biosimilars sponsors.
Samsung Bioepis Presents Phase III Data For Eylea Biosimilar
Samsung Bioepis presented three new studies on two of its blockbuster biosimilars at the American Academy of Ophthalmology 2022 Annual Meeting, including Phase III data for its proposed aflibercept rival to Eylea.